November 19, 2016

Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial

ASN 2016 High Impact Clinical Trial Johannes F. Mann, Kristine Brown Fandsen, Gilbert Daniels, Peter Kristensen, Michael Nauck, Steve Nissen, Stuart Pocock, Neil Poulter, Soren Rasmussen, William Steinberg, Mette Stockner, Bernard Zinman, Florian Baeres, Richard Bergenstal, Steve Marso, John Buse. Erlangen, Germany. Liraglutide, as compared to placebo, was studied in a RCT of 9340 high-risk […]

Leave a Comment! Posted in Clinical Trial Results, Conference Alert
November 19, 2016

Remote ischaemic preconditioning (RIPC) leads to sustained improvement in allograft function following live donor (LD) kidney transplantation: 5 year follow up in the REnal Protection Against Ischaemia Reperfusion in transplantation (REPAIR) study

ASN 2016 High Impact Clinical Trial Kristin Veighey, Jennifer Nicholas, Tim Clayton, Raymond Macallister Using 4 cycles of ischemia/reperfusion in the preoperative living donors, remote ischemic preconditioning (RIPC) was evaluated regarding its impact on post-tranplant outcomes.  The primary endpoint was iohexal GFR at 12 months and secondary endpoints were change in eGFR, graft loss or death. […]

Leave a Comment! Posted in Clinical Trial Results, Conference Alert
November 19, 2016

Efficacy and Safety of Sparsentan, a Dual Angiotensin II (Ang II) and Endothelin (ET) Type A Receptor Antagonist, in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Phase 2 Trial (DUET)

High Impact Clinical Trials ASN 2016 Howard Trachtman, Peter J. Nelson, Radko Komers In the phase 2 DUET trial that included 96 patients with focal segmental glomerulosclerosis (FSGS), sparsentan, a dual angiotensin II and endothelin type A receptor antagonist, was evaluated to determine the impact on proteinuria. As compared to irbesartan, urinary protein excretion was […]

2 Comments Posted in Clinical Trial Results, Conference Alert
November 19, 2016

AURA-LV: Successful Treatment of Active Lupus Nephritis with Voclosporin

ASN 2016 High Impact Clinical Trial William Franklin Pendergraft, James A. Tumlin, Brad H. Rovin, Mary Anne Dooley, David R.W. Jayne, David Wofsy, Frederic A. Houssiau, David Isenberg, Tak Mao Chan, Neil Solomons, Robert B. Huizinga In patients with biopsy proven lupus nephritis, complete remission at 24 weeks was reached by 32.6% (p = 0.045) […]

18 Comments Posted in Clinical Trial Results, Conference Alert
November 19, 2016

The Sodium Lowering in Dialysate (SoLID) Trial: A Randomised Controlled Trial of Low versus Standard Dialysate Sodium Concentration (DNa) during Hemodialysis (HD) for Regression of Left Ventricular (LV) Mass

ASN 2016 High Impact Clinical Trial Mark R. Marshall, Alain C. Vandal, Joanna Leigh Dunlop, Janak Rashme de Zoysa, Imad A. Haloob, Christopher J. Hood, John Irvine, Philip J. Matheson, David Mcgregor, Kannaiyan Samuel Rabindranath, David Semple. Auckland, New Zealand. Dialysate sodium (Na) concentration of 135 mmol/L vs 140 mmol/L did not effectively reduce left ventricular […]

1 Comment Posted in Clinical Trial Results, Conference Alert
November 19, 2016

ASN 2016 Rabbit-ATG or Basiliximab Induction for Rapid Steroid Withdrawal after Renal Transplantation: An Open-Label, Multicentre, Randomized Controlled Trial

High Impact Clinical Trial Session at the 2016 ASN Christian Hugo, Michael Sean Wiesener, Mirian Opgenoorth, Oliver Thomusch. Dresden, Germany In low-tacrolimus treated, immunologically low-risk renal transplant recipients, rapid steroid withdrawal is safe with no impact on survival or biopsy-proven acute rejection.  Post-transplantation diabetes incidence is reduced from 39.2% to 23.9%(Basiliximab) or 22.7% (rATG) in […]

Leave a Comment! Posted in Clinical Trial Results, Conference Alert
November 11, 2016

The Risk of Major Hemorrhage with CKD

.   .   

This retrospective cohort study (2002-2010)  grouped 516,197 adults ≥40 years old by eGFR (≥90, 60 to <90, 45 to <60, 30 to <45, 15 to <30, or <15 ml/min per 1.73 m(2)) and urine albumin-to-creatinine ratio (ACR; >300, 30-300, or <30 mg/g) to examine incidence of hemorrhage. The 3-year cumulative incidence of hemorrhage increased 20-fold across declining eGFR […]

Leave a Comment! Posted in Chronic Kidney Disease, Clinical Nephrology, General Nephrology
November 11, 2016

Proton Pump Inhibitors and Risk of Incident CKD & Progression to ESRD

.   .   

The Department of Veterans Affairs national databases were used in this study to build a primary cohort of new users of PPI (n=173,321) and new users of histamine H2-receptor antagonists (H2blockers; n=20,270.  These patients were followed for over 5 years to ascertain renal outcomes. In adjusted Cox survival models, the PPI group, compared with the […]

Leave a Comment! Posted in Chronic Kidney Disease, Clinical Nephrology, General Nephrology
November 11, 2016

Hospitalization Rates for Patients on Assisted Peritoneal Dialysis Compared with In-Center Hemodialysis

.   .   

This multicenter, retrospective cohort study by linked a quality assurance dataset to administrative health data in Ontario, Canada. The study included 872 patients in the in-center hemodialysis group and 203 patients in the assisted peritoneal dialysis group. Using an intention to treat approach, patients on assisted peritoneal dialysis had a similar hospitalization rate of 11.1 d/yr (95% confidence interval, 9.4 to 13.0) compared with 12.9 d/yr (95% confidence interval, 10.3 to 16.1) in the hemodialysis group (P=0.19). […]

Leave a Comment! Posted in Clinical Nephrology, Hemodialysis, Peritoneal Dialysis
November 11, 2016

Pathophysiology of Renal Tubular Acidosis: Core Curriculum 2016

.   .   

This core curriculum is a valuable resource in deconstructing the pathophysiology of renal tubular acidosis.        

Leave a Comment! Posted in AJKD Core Curriculum, Clinical Nephrology
November 11, 2016

Continuous Dialysis Therapies: Core Curriculum 2016

.   .   

This edition of the core curriculum nicely summarizes continuous dialysis therapies.        

Leave a Comment! Posted in AJKD Core Curriculum, Hemodialysis
November 11, 2016

The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases

.   .   

This study measured the urine protein and creatinine centrally in random and 24-hour urine collections at biopsy and longitudinally every 6 months in individuals participating in the Nephrotic Syndrome Study Network (NEPTUNE) cohort with glomerular disease. The results show that in patients with glomerular disease and proteinuria, the urine protein creatinine ratio correlates only moderately with 24-hour urine protein excretion. The results were used to develop estimating equation to derive 24-hour urine protein excretion from random urine protein creatinine ratio values with improved precision. […]

Leave a Comment! Posted in Clinical Nephrology, General Nephrology, Glomerulonephritis
November 11, 2016

A new model to predict acute kidney injury requiring renal replacement therapy after cardiac surgery

.   .   

The authors of this study developed and validated a risk prediction model for acute kidney injury requiring renal replacement therapy within 14 days after cardiac surgery.  They identified 8 independent predictors of acute kidney injury requiring renal replacement therapy in the derivation model(adjusted odds ratio, 95% confidence interval [CI]): congestive heart failure (3.03, 2.00-4.58), Canadian Cardiovascular Society angina class III or higher (1.66, […]

Leave a Comment! Posted in Acute Kidney Injury, Clinical Nephrology, Hemodialysis